COMPASS Pathways plc (CMPS)
After hours:
- GlobeNewswire
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Hear Professor David Hellerstein talk about the study Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today presented positive data from the largest randomised, controlled, double-blind study of psilocybin therapy ever completed, at the Ameri
- Simply Wall St.
Could The COMPASS Pathways plc (NASDAQ:CMPS) Ownership Structure Tell Us Something Useful?
The big shareholder groups in COMPASS Pathways plc ( NASDAQ:CMPS ) have power over the company. Insiders often own a...
- GlobeNewswire
COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: Citi’s Biopharma Virtual Co-Panel Day: panel “Mood Disorders/Mental Health Panel” at 11:00 am ET on 18 May 2022HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24 May 2022 A live audio webcast of
